INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 451m ago
HOUSE PTR50m ago
SEC 13F50m ago
ROBINHOOD CHAIN50m ago
SEC FORM 4/Tax withholdingVerified data

Taylor Ben R reported RXRX

Chief Financial Officer · RECURSION PHARMACEUTICALS, INC. · Class A Common Stock

Side
F
Value
$149K
Shares
48.0K
Price
$3.11
Executed
Apr 6, 2026
Disclosed
Apr 8, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Apr 6 executedApr 8, 2026 disclosed

RXRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+4 / 25

$149K reported value · 4.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · RXRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    HF
    Hassan FredDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Grant or award
    		A—
    156.7K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    4
    BB
    Borgeson BlakeDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$155K
    40.0K sh
    		Nov 3, 2026Nov 4, 2026
    traded Nov 3, 2026
    		+1dSEC FORM 4

    Evidence

    11
    KN
    Khan NajatDirector, CEO and President
    RXRXRECURSION PHARMACEUTICALS, INC.
    Tax withholding
    		F$254K
    80.5K sh
    		Aug 17, 2026Aug 18, 2026
    traded Aug 17, 2026
    		+1dSEC FORM 4

    Evidence

    12
    HD
    Hallett DavidChief Scientific Officer
    RXRXRECURSION PHARMACEUTICALS, INC.
    Tax withholding
    		F$84K
    26.7K sh
    		Aug 17, 2026Aug 18, 2026
    traded Aug 17, 2026
    		+1dSEC FORM 4

    Evidence

    0
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Derivative conversion · 10b5-1 plan
    		C—
    40.0K sh
    		Jun 5, 2026Jun 5, 2026
    traded Jun 5, 2026
    		+0dSEC FORM 4

    Evidence

    23
    KN
    Khan NajatDirector, CEO and President
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$84K
    23.6K sh
    		Jun 5, 2026Jun 5, 2026
    traded Jun 5, 2026
    		+0dSEC FORM 4

    Evidence

    0
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Derivative conversion · 10b5-1 plan
    		C—
    40.0K sh
    		Jun 5, 2026Jun 5, 2026
    traded Jun 5, 2026
    		+0dSEC FORM 4

    Evidence

    16
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$145K
    40.0K sh
    		Jun 5, 2026Jun 5, 2026
    traded Jun 5, 2026
    		+0dSEC FORM 4

    Evidence

    19
    BB
    Borgeson BlakeDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$110K
    30.0K sh
    		Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    		+2dSEC FORM 4

    Evidence

    24
    BN
    Bumpus NamandjeDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$16K
    4,386 sh
    		Jun 3, 2026Jun 4, 2026
    traded Jun 3, 2026
    		+1dSEC FORM 4

    Evidence

    12
    HD
    Hallett DavidChief Scientific Officer
    RXRXRECURSION PHARMACEUTICALS, INC.
    Tax withholding
    		F$81K
    26.7K sh
    		May 15, 2026May 19, 2026
    traded May 15, 2026
    		+4dSEC FORM 4

    Evidence

    12
    KN
    Khan NajatDirector, CEO and President
    RXRXRECURSION PHARMACEUTICALS, INC.
    Tax withholding
    		F$191K
    62.7K sh
    		May 15, 2026May 19, 2026
    traded May 15, 2026
    		+4dSEC FORM 4

    Evidence

    9
    BB
    Borgeson BlakeDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$106K
    30.0K sh
    		May 5, 2026May 7, 2026
    traded May 5, 2026
    		+2dSEC FORM 4

    Evidence

    0
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Derivative conversion · 10b5-1 plan
    		C—
    40.0K sh
    		Apr 22, 2026Apr 24, 2026
    traded Apr 22, 2026
    		+2dSEC FORM 4

    Evidence

    6
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$144K
    40.0K sh
    		Apr 22, 2026Apr 24, 2026
    traded Apr 22, 2026
    		+2dSEC FORM 4

    Evidence

    0
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Derivative conversion · 10b5-1 plan
    		C—
    40.0K sh
    		Apr 22, 2026Apr 24, 2026
    traded Apr 22, 2026
    		+2dSEC FORM 4

    Evidence

    0
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Derivative conversion · 10b5-1 plan
    		C—
    40.0K sh
    		Apr 7, 2026Apr 8, 2026
    traded Apr 7, 2026
    		+1dSEC FORM 4

    Evidence

    6
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$124K
    40.0K sh
    		Apr 7, 2026Apr 8, 2026
    traded Apr 7, 2026
    		+1dSEC FORM 4

    Evidence

    0
    GC
    Gibson ChristopherDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Derivative conversion · 10b5-1 plan
    		C—
    40.0K sh
    		Apr 7, 2026Apr 8, 2026
    traded Apr 7, 2026
    		+1dSEC FORM 4

    Evidence

    9
    BB
    Borgeson BlakeDirector
    RXRXRECURSION PHARMACEUTICALS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$93K
    30.0K sh
    		Apr 7, 2026Apr 8, 2026
    traded Apr 7, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001712276-26-000003
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 6, 2026
    Published
    Apr 8, 2026
    Ingested by INSIDER
    Nov 5, 04:06 UTC
    Last re-read
    Nov 5, 04:07 UTC

    Extracted facts

    Filer
    Taylor Ben R
    Role
    Chief Financial Officer
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    RECURSION PHARMACEUTICALS, INC.
    Ticker
    RXRX
    Shares
    48.0K
    Price per share
    $3.11
    Value
    $149,367
    Execution date (reported)
    Apr 6, 2026
    Owned after transaction
    1.13M shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 48.0K
    • Price: $3.11

    = $149,367

    What this establishes

    Taylor Ben R filed this Form 4 reporting a tax withholding of RXRX on Apr 6, 2026. It became public on Apr 8, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Taylor Ben Rcik:0001712276
    Issuer
    RECURSION PHARMACEUTICALS, INC.cik:0001601830

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.